New England Journal of Medicine· 2017Q1

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González, Piotr Rutkowski et al.

5,405citations
Q1SCImago
2017year

Short summary

Combination nivolumab and ipilimumab therapy resulted in a 3-year overall survival rate of 58% in advanced melanoma patients, compared to 34% for ipilimumab alone (hazard ratio 0.55, P<0.001).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Oncology

OncologyMedicine